Cited by CrossRef (7)
- Pu Cao, Xiaoyan Yang, Daquan Liu, Simin Ye, Wei Yang, Zhizhong Xie, Xiaoyong Lei.
Research progress of
PD‐L1
non‐glycosylation in cancer immunotherapy
. Scand J Immunol 2022;96
- Hongjian Yang, Yuxi Miao, Zhaojin Yu, Minjie Wei, Xue Jiao. Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. Front. Oncol. 2023;13
- Jia-Shiong Chen, Yi-Chien Hsieh, Cheng-Han Chou, Yi-Hong Wu, Mu-Hsuan Yang, Sz-Hao Chu, Ye-Su Chao, Chia-Nan Chen. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. IJMS 2022;23:10677
- Min Xin, Dan Lin, Nahan Yan, Huiling Li, Jieping Li, Zongming Huang. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model. 2022;33:117
- Jii Bum Lee, Hye Ryun Kim, Sang-Jun Ha. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Netw 2022;22
- Liza C. Villaruz, George R. Blumenschein, Gregory A. Otterson, Ticiana A. Leal. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer 2023
- Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sébastien Wälchli, Magdalena Winiarska, Radoslaw Zagozdzon. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer 2022;10:e002500
